SearchHURST advises on sale of HCD Economics to Prime Global
HURST Corporate Finance has advised the shareholders of HCD Economics on its sale to medical communications business Prime Global.
HCD is based at Daresbury, Cheshire, and has offices in Poland and Spain.
Its team of around 50 focus on health economics and outcomes research and real-world evidence, conducting disease research and burden of illness studies to address health technology assessment and health economic evidence needs for market access, pricing and reimbursement across the UK, key European markets and the United States.
It works with academic institutions, including the University of Chester, charities, patient advocates, clinicians, local and national health services and the pharmaceutical industry to inform and support healthcare decision-making.
Prime Global, which is based in Knutsford, Cheshire, provides the world’s leading biotech, pharma and healthcare businesses with full-service professional communications, including healthcare strategy and consultancy, scientific and medical communications, consumer health, patient services and market access.
Founded in 1997 by chief executive and managing director Graeme Peterson, it comprises a number of agencies and consultancies and employs over 300 people across the UK and US.
Graeme said: “HCD Economics and Prime Global are both focused on improving patients’ lives. Combining HCD’s evidence generation and analytic expertise with our specialist medical, patient, and payer communications skills will strengthen our support to clients, helping ensure patients have timely access to innovative treatments.
“I am excited to see the synergies we will create as our new partnership unfolds.”
Jamie O’Hara, founder and CEO of HCD Economics, said: “I’m delighted to partner with Prime Global, who share our desire for improving patient lives. I founded HCD Economics to combine my expertise in evidence generation and real-world insights with my passion for advocacy. I look forward to working with Prime Global’s patient-led scientific and communications teams to take us to the next level.”
Chief financial officer Paul Johnston said: “HURST was appointed to represent us and assist in the negotiation and completion of our deal and proved a great asset to our team, being always accessible for queries no matter how complex, and enabling us to focus on other areas of the deal and the day-to-day running of the business.”
Lauren Roberts of HURST Corporate Finance said: “It’s been a pleasure to advise the shareholders of HCD Economics on the company’s sale to Prime Global.
“HCD has an excellent reputation and has gone from strength to strength in recent years. Prime Global is a great fit to enable HCD to get to the next level. We wish the HCD and Prime Global team all the best for the future.”
This is the latest deal HURST has advised upon in the sector, having last year advised Bioscript on a significant investment by Sovereign Capital Partners. HURST later advised Fortis Pharma Consulting on its sale to Bioscript.